Moody Lynn Lieberson & Walker LLC Boosts Stake in Johnson & Johnson $JNJ

Key Points

• Moody Lynn Lieberson & Walker LLC increased its Johnson & Johnson stake by 6.4% in the second quarter, adding 8,097 shares to own 134,657 shares worth approximately $34.2 million. Institutional investors collectively hold 69.55% of JNJ’s shares.
• Analysts maintain a generally positive view, with JNJ carrying a consensus “Moderate Buy” rating and an average price target of $268.22. Recent targets range as high as $300.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations, reporting adjusted EPS of $2.90 and revenue of $25.31 billion, up 6.6% year over year. The company also declared a $1.34 quarterly dividend, equivalent to a 2.1% annualized yield.

Moody Lynn Lieberson & Walker LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,657 shares of the company's stock after acquiring an additional 8,097 shares during the quarter. Johnson & Johnson comprises 1.8% of Moody Lynn Lieberson & Walker LLC's investment portfolio, making the stock its 17th biggest position. Moody Lynn Lieberson & Walker LLC's holdings in Johnson & Johnson were worth $34,199,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of JNJ. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $26,000. DecisionPoint Financial LLC boosted its stake in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after buying an additional 75 shares during the last quarter. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC grew its holdings in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on JNJ. Wells Fargo & Company lifted their price target on Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a research note on Wednesday, April 15th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $268.22.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 48,972 shares of company stock worth $12,295,205 over the last ninety days. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ opened at $260.74 on Thursday. The company's 50-day moving average price is $250.68 and its 200 day moving average price is $240.77. Johnson & Johnson has a 12-month low of $172.70 and a 12-month high of $274.90. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $628.36 billion, a P/E ratio of 30.21, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter last year, the firm posted $2.77 earnings per share. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson's payout ratio is presently 62.11%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is advancing seltorexant into late-stage development for major depressive disorder, potentially adding a novel growth opportunity to its Innovative Medicine pipeline. The company also announced a multiyear partnership with ACCESS to expand advanced cardiac electrophysiology technologies in ambulatory surgery centers, supporting its higher-growth MedTech strategy. Johnson & Johnson Advances Seltorexant and Expands Outpatient Cardiac Care
• Positive Sentiment: Recent catalysts include FDA De Novo authorization for the OTTAVA robotic surgery system, Priority Review for RYBREVANT FASPRO and a collaboration on in-vivo CAR-T therapies. These developments strengthen JNJ’s long-term growth narrative beyond its established products. What Johnson & Johnson’s OTTAVA FDA Win and Talc Deal Shift Mean for Shareholders
• Positive Sentiment: JNJ’s latest quarterly results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. Management raised its full-year 2026 EPS outlook to $11.60-$11.75, reinforcing confidence in the business. Johnson & Johnson vs. Medtronic After Earnings
• Positive Sentiment: JNJ remains attractive to income-focused investors because of its long record of uninterrupted dividend increases, diversified operations and relatively strong balance sheet. Johnson & Johnson vs. AbbVie: Safe Dividend vs. Higher Yield

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source